UK peptide therapeutics market is anticipated to project a CAGR of 3.7%, during the forecast period. The UK is estimated to hold a considerable market share in the peptide therapeutics market in the European region during the forecast period. The major factor that contributes to the country’s high market share is continuously increasing healthcare spending per capita coupled with a significant prevalence of cancer. 

The increasing prevalence of cancer in the country is one of the key factors which is expected to promote the demand for advanced treatment solutions, such as peptide therapeutics. Well established healthcare infrastructure is also one of the key reasons which are expected to promote the acceptance of peptide therapeutics for the treatment of various diseases such as cancer, gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others, thereby, driving the growth of the market in the near future.

Visit for Global Peptide Therapeutics Market Report at: https://www.omrglobal.com/industry-reports/peptide-therapeutics-market

UK peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, metabolic disorder dominates the market in UK. The increasing prevalence of diabetes globally created demand for insulin and hence drives the market growth.

Furthermore, some of the global players operating in the market include Novo Nordisk A/S, AstraZeneca Plc, GlaxoSmithKline PLC, Sanofi SA, and Novartis International AG. These companies are using several strategies to expand market share and gain a competitive advantage over their competitors. The strategies include new product launches, mergers and acquisitions, partnerships, and collaborations. 

For instance, in July 2020, ProteinQure, a computational protein drug discovery company, declared a collaboration with AstraZeneca to apply structure-based design to the creation of therapeutic libraries to accelerate the R&D of peptide therapeutics. The partnership will accelerate ProteinQure's expertise in structure-based drug design and computational methods. AstraZeneca will conduct experimental validation, drawing on its extensive expertise in biologics.

Research Methodology

The market study of the UK peptide therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Authentic public databases 
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for drug manufacturing companies, pharmaceutical companies, insulin manufacturers, diabetes management companies, government organizations, regulatory bodies, hospitals & pharmacies, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models. 

Market Segmentation:

1. UK Peptide Therapeutics Market Research and Analysis by Route of Administration
2. UK Peptide Therapeutics Market Research and Analysis by Application

The Report Covers:

• Comprehensive research methodology of the UK peptide therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK peptide therapeutics market.
• Insights about market determinants which are stimulating the UK peptide therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.